Our Company
is committed to promoting health across communities
What does Nordic Pharma do?
Nordic Pharma sells uniquely positioned generics that bring value to customers and patients.
We spend every minute of every day figuring out how to bring historically complex prescription medications to market. Our products are generics of value to the market, not high-volume, mass-produced products.
Our Executive Team
We believe that we can deliver a better quality of life and health to the people in our communities, our families and the world.
Sean Davis
Chief Executive Officer
Jai Parekh, MD, MBA, FAAO
Chief Commercial Officer
Joanna Arensburg
Chief Financial Officer, Controller & Treasurer
Marina Volin, Esq.
Senior Vice President, General Counsel & Corporate Secretary
Todd Love
Senior Vice President, Commercial
Nancy Fulginiti
Vice President, Quality
Melissa Goodhead
Head, Regulatory Affairs & Compliance
Raul Baez
Director, Supply Chain and Operations
Aaron Graff
Board Member
Dennis Schut
Board Member
Our History
We may be new to the market, but we share the technology, maturity and capability of a nearly 70 year-old healthcare group.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.
1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..
2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.
2023
Nordic Pharma Group B.V. through its subsidiary Amring Pharmaceuticals Inc., completes acquisition of Visant Medical.
2024
Amring Pharmaceuticals Inc. announces name change to Nordic Pharma, Inc. under new Nordic Group, B.V. ownership.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.
2024
Amring Pharmaceuticals Inc. announces name change to Nordic Pharma, Inc. under new Nordic Group, B.V. ownership.
1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.
2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
2023
Nordic Pharma Group B.V. through its subsidiary Amring Pharmaceuticals Inc., completes acquisition of Visant Medical.
Nordic Pharma, Inc. is a proud member of the global pharmaceutical community.
Our strong global network of drug technology and manufacturing gives us the quality and regulatory capability to meet the demands of various niche markets.
